Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

By sjmartinez • July 18, 2023

Belperio J, Nguyen T, Lombardi DA, Bogus M, Moskalenko V, Singh D, Haumann B, Bourdet DL, Kaufman E, Pfeifer ND, Thompson CG, Woo J, Moran EJ, Saggar R. Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respir Res. 2023 Jul;10(1):e001627. doi: 10.1136/bmjresp-2023-001627. PMID: 37460276.

Tags: covid-19, Nebuliser therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test

Zeng W, Liu CC, Li S, Zhou Y, Stackpole ML, Xiao Y, Hu R, Tang C, Liu Q, Zeng W, Yeh A, Melehy A, Tran[...]

Clinician Perceptions of the Impact of Switching HPV Vaccine Initiation to 9-10 Years

Szilagyi PG, Gurfinkel D, Clark E, Albertin C, Saville A, O'Leary ST, Beaty B, Vangala S, Woo H, Golden C, Singh J, Kempe A. Clinician[...]

Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis

Umbleja T, Zafar MU, McCallum S, Gattu AK, Zanni MV, Bloomfield GS, Malvestutto CD, Fichtenbaum CJ, Currier JS, Sponseller CA, Diggs MR, Chu SM, Lu[...]